Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarter 2022 Financial Results
04:05pm, Monday, 01'st Aug 2022
WALTHAM, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will hos
Apellis Pharmaceuticals, Inc. (APLS) Moves 16.3% Higher: Will This Strength Last?
10:08am, Wednesday, 20'th Jul 2022
Apellis Pharmaceuticals, Inc. (APLS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there cou
HC Wainwright Initiates Coverage On Upcoming Complement Franchise Company Apellis Pharmaceuticals
01:15pm, Tuesday, 19'th Jul 2022
HC Wainwright has initiated coverage on Apellis Pharmaceuticals Inc (NASDAQ: APLS) with a Buy rating and a $75 price target. The analyst expects Apellis's C3 inhibitor, pegcetacoplan, to be appro
Apellis Pharmaceuticals Stock Jumps After FDA Accepts Drug for Review
09:35am, Tuesday, 19'th Jul 2022
Pegcetacoplan aims to treat a cause of blindness that affects more than 1 million Americans.
Why Apellis Pharmaceuticals Stock Is Soaring
09:18am, Tuesday, 19'th Jul 2022
Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading higher Tuesday after the company announced the U.S. Food and Drug Administration accepted and granted priority review designation for t
Apellis gets Priority Review designation for geographic atrophy therapy
08:11am, Tuesday, 19'th Jul 2022
Shares of Apellis Pharmaceuticals Inc. APLS, -2.84% jumped 24.5% in premarket trading on Tuesday after the company said it received a Priority Review designation from the Food and Drug Administration
Apellis: Mixed Data, But Definitely Approvable In GA
03:10am, Saturday, 25'th Jun 2022
Apellis has one product approved in one indication, and an NDA submitted in a second indication, geographic atrophy or GA. Data from two phase 3 trials were mixed.
Apellis (APLS) Expands Deal for Targeted Complement Therapies
03:55pm, Thursday, 23'rd Jun 2022 Zacks Investment Research
Apellis (APLS) expands its current research and development deal with privately held company, Affilogic, to develop targeted complement therapies for delivery into the brain.
Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress
07:00am, Friday, 10'th Jun 2022 GlobeNewswire Inc.
WALTHAM, Mass. and STOCKHOLM, Sweden, June 10, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO:SOBI) today reported new analyses of Phase 3 studies that reinfor
Apellis (APLS), Sobi Begin Pegcetacoplan Dosing in Kidney Disease
02:14pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
Apellis (APLS) and Sobi dose the first patient in phase III VALIANT study evaluating pegcetacoplan in primary immune-complex membranoproliferative glomerulonephritis and C3 glomerulopathy. Stock up.
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Monday, 06'th Jun 2022 GlobeNewswire Inc.
WALTHAM, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approve
Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 4.5% Since Last Earnings Report?
03:32pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Apellis (APLS) Files NDA for Pegcetacoplan in Geographic Atrophy
04:09pm, Thursday, 02'nd Jun 2022 Zacks Investment Research
Apellis (APLS) submits a new drug application to the FDA for pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
Apellis (APLS) Files NDA for Pegcetacoplan in Geographic Atrophy
01:33pm, Thursday, 02'nd Jun 2022
Apellis (APLS) submits a new drug application to the FDA for pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
08:05pm, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will pa
